Skip to main content
Erschienen in: World Journal of Surgery 5/2020

07.01.2020 | Original Scientific Report

Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less

verfasst von: Youngkyu Moon, Si Young Choi, Jae Kil Park, Kyo Young Lee

Erschienen in: World Journal of Surgery | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

In the seventh edition TNM staging system for lung cancer, a high maximum standardized uptake value (SUVmax) on positron emission tomography was regarded as a risk factor for occult lymph node metastasis in clinical T1N0 non-small cell lung cancer (NSCLC). However, in the eighth edition TNM classification, tumors are classified according to the size of the invasive component only, and those with invasive component size ≤3 cm are diagnosed as stage T1. The aim of this study was to reassess the risk factors for occult lymph node metastasis under the eighth edition TNM classification for lung cancer.

Methods

From 2010 to 2017, 553 patients with clinical N0 peripheral NSCLC with invasive component size ≤3 cm underwent anatomical lobectomy with systematic lymph node dissection. We analyzed these cases retrospectively to identify risk factors for postoperative nodal upstaging.

Results

Among 553 study patients, 54 (9.8%) had nodal upstaging after surgery. In multivariate analysis adopting the eighth edition TNM classification for lung cancer, serum carcinoembryonic antigen (CEA) level (hazard ratio [HR] = 1.113, p = 0.002), invasive component size (HR = 2.398, p = 0.004), visceral pleural invasion (HR = 2.901, p = 0.005), and lymphatic invasion (HR = 9.336, p < 0.001) were significant risk factors for nodal upstaging, but SUVmax was not.

Conclusion

SUVmax is not a predictor of nodal upstaging in clinical N0 peripheral NSCLC with invasive component size ≤3 cm under the eighth edition TNM classification for lung cancer. Significant risk factors of occult lymph node metastasis are serum CEA level, tumor invasive component size, visceral pleural invasion, and lymphatic invasion.
Literatur
1.
Zurück zum Zitat Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622 (discussion 622–613) CrossRef Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622 (discussion 622–613) CrossRef
2.
Zurück zum Zitat De Leyn P, Dooms C, Kuzdzal J et al (2014) Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 45:787–798CrossRef De Leyn P, Dooms C, Kuzdzal J et al (2014) Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 45:787–798CrossRef
3.
Zurück zum Zitat Moon Y, Kim KS, Lee KY et al (2016) Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg 101:1928–1935CrossRef Moon Y, Kim KS, Lee KY et al (2016) Clinicopathologic factors associated with occult lymph node metastasis in patients with clinically diagnosed N0 lung adenocarcinoma. Ann Thorac Surg 101:1928–1935CrossRef
4.
Zurück zum Zitat Ghaly G, Rahouma M, Kamel MK et al (2017) Clinical predictors of nodal metastases in peripherally clinical T1a N0 non-small cell lung cancer. Ann Thorac Surg 104:1153–1158CrossRef Ghaly G, Rahouma M, Kamel MK et al (2017) Clinical predictors of nodal metastases in peripherally clinical T1a N0 non-small cell lung cancer. Ann Thorac Surg 104:1153–1158CrossRef
5.
Zurück zum Zitat Ye B, Cheng M, Li W et al (2014) Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 98:217–223CrossRef Ye B, Cheng M, Li W et al (2014) Predictive factors for lymph node metastasis in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 98:217–223CrossRef
6.
Zurück zum Zitat Miyasaka Y, Suzuki K, Takamochi K et al (2013) The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer. Eur J Cardiothorac Surg 44:83–87CrossRef Miyasaka Y, Suzuki K, Takamochi K et al (2013) The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer. Eur J Cardiothorac Surg 44:83–87CrossRef
7.
Zurück zum Zitat Li M, Wu N, Zheng R et al (2013) Primary tumor PET/CT [(1)(8)F]FDG uptake is an independent predictive factor for regional lymph node metastasis in patients with non-small cell lung cancer. Cancer Imaging 12:566–572CrossRef Li M, Wu N, Zheng R et al (2013) Primary tumor PET/CT [(1)(8)F]FDG uptake is an independent predictive factor for regional lymph node metastasis in patients with non-small cell lung cancer. Cancer Imaging 12:566–572CrossRef
8.
Zurück zum Zitat Moon Y, Park JK, Lee KY et al (2018) Consolidation/tumor ratio on chest computed tomography as predictor of postoperative nodal upstaging in clinical T1N0 lung cancer. World J Surg 42(9):2872–2878CrossRef Moon Y, Park JK, Lee KY et al (2018) Consolidation/tumor ratio on chest computed tomography as predictor of postoperative nodal upstaging in clinical T1N0 lung cancer. World J Surg 42(9):2872–2878CrossRef
9.
Zurück zum Zitat Moon Y, Sung SW, Namkoong M et al (2016) The effectiveness of mediastinal lymph node evaluation in a patient with ground glass opacity tumor. J Thorac Dis 8:2617–2625CrossRef Moon Y, Sung SW, Namkoong M et al (2016) The effectiveness of mediastinal lymph node evaluation in a patient with ground glass opacity tumor. J Thorac Dis 8:2617–2625CrossRef
10.
Zurück zum Zitat Lu P, Sun Y, Sun Y et al (2014) The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma. Lung Cancer 85:53–58CrossRef Lu P, Sun Y, Sun Y et al (2014) The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma. Lung Cancer 85:53–58CrossRef
11.
Zurück zum Zitat Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51CrossRef Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51CrossRef
12.
Zurück zum Zitat Travis WD, Asamura H, Bankier AA et al (2016) The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 11:1204–1223CrossRef Travis WD, Asamura H, Bankier AA et al (2016) The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 11:1204–1223CrossRef
13.
Zurück zum Zitat Heineman DJ, Ten Berge MG, Daniels JM et al (2016) The quality of staging non-small cell lung cancer in the Netherlands: data from the Dutch lung surgery audit. Ann Thorac Surg 102:1622–1629CrossRef Heineman DJ, Ten Berge MG, Daniels JM et al (2016) The quality of staging non-small cell lung cancer in the Netherlands: data from the Dutch lung surgery audit. Ann Thorac Surg 102:1622–1629CrossRef
14.
Zurück zum Zitat Heineman DJ, Ten Berge MG, Daniels JM et al (2016) Clinical staging of stage I non-small cell lung cancer in the Netherlands-need for improvement in an era with expanding nonsurgical treatment options: data from the Dutch lung surgery audit. Ann Thorac Surg 102:1615–1621CrossRef Heineman DJ, Ten Berge MG, Daniels JM et al (2016) Clinical staging of stage I non-small cell lung cancer in the Netherlands-need for improvement in an era with expanding nonsurgical treatment options: data from the Dutch lung surgery audit. Ann Thorac Surg 102:1615–1621CrossRef
15.
Zurück zum Zitat Suh JH, Park JK, Moon Y (2018) Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule. J Thorac Dis 10:3005–3015CrossRef Suh JH, Park JK, Moon Y (2018) Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule. J Thorac Dis 10:3005–3015CrossRef
16.
Zurück zum Zitat Rami-Porta R, Asamura H, Travis WD et al (2017) Lung cancer—major changes in the American joint committee on cancer eighth edition cancer staging manual CA cancer. J Clin 67:138–155 Rami-Porta R, Asamura H, Travis WD et al (2017) Lung cancer—major changes in the American joint committee on cancer eighth edition cancer staging manual CA cancer. J Clin 67:138–155
17.
Zurück zum Zitat Yamazaki K, Yoshino I, Yohena T et al (2007) Clinically predictive factors of pathologic upstaging in patients with peripherally located clinical stage IA non-small cell lung cancer. Lung Cancer 55:365–369CrossRef Yamazaki K, Yoshino I, Yohena T et al (2007) Clinically predictive factors of pathologic upstaging in patients with peripherally located clinical stage IA non-small cell lung cancer. Lung Cancer 55:365–369CrossRef
18.
Zurück zum Zitat Rami-Porta R, Wittekind C, Goldstraw P (2005) Complete resection in lung cancer surgery: proposed definition. Lung Cancer 49:25–33CrossRef Rami-Porta R, Wittekind C, Goldstraw P (2005) Complete resection in lung cancer surgery: proposed definition. Lung Cancer 49:25–33CrossRef
19.
Zurück zum Zitat Watanabe S, Asamura H (2009) Lymph node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol 4:652–657CrossRef Watanabe S, Asamura H (2009) Lymph node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol 4:652–657CrossRef
20.
Zurück zum Zitat Darling GE, Allen MS, Decker PA et al (2011) Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American college of surgeons oncology group trial. Chest 139:1124–1129CrossRef Darling GE, Allen MS, Decker PA et al (2011) Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American college of surgeons oncology group trial. Chest 139:1124–1129CrossRef
21.
Zurück zum Zitat Dai J, Liu M, Yang Y et al (2019) Optimal lymph node examination and adjuvant chemotherapy for stage I lung cancer. J Thorac Oncol 14(7):1277–1285CrossRef Dai J, Liu M, Yang Y et al (2019) Optimal lymph node examination and adjuvant chemotherapy for stage I lung cancer. J Thorac Oncol 14(7):1277–1285CrossRef
22.
Zurück zum Zitat Hishida T, Miyaoka E, Yokoi K et al (2016) Lobe-specific nodal dissection for clinical stage I and II NSCLC: japanese multi-institutional retrospective study using a propensity score analysis. J Thorac Oncol 11:1529–1537CrossRef Hishida T, Miyaoka E, Yokoi K et al (2016) Lobe-specific nodal dissection for clinical stage I and II NSCLC: japanese multi-institutional retrospective study using a propensity score analysis. J Thorac Oncol 11:1529–1537CrossRef
23.
Zurück zum Zitat Adachi H, Sakamaki K, Nishii T et al (2017) Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. J Thorac Oncol 12:85–93CrossRef Adachi H, Sakamaki K, Nishii T et al (2017) Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: a propensity score matching study. J Thorac Oncol 12:85–93CrossRef
Metadaten
Titel
Risk Factors for Occult Lymph Node Metastasis in Peripheral Non-Small Cell Lung Cancer with Invasive Component Size 3 cm or Less
verfasst von
Youngkyu Moon
Si Young Choi
Jae Kil Park
Kyo Young Lee
Publikationsdatum
07.01.2020
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 5/2020
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05365-5

Weitere Artikel der Ausgabe 5/2020

World Journal of Surgery 5/2020 Zur Ausgabe

Editorial Perspective

Editorial

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.